SIRION Biotech Licenses Adenovirus Technology to Danish Startup, InProTher for its Novel Immunotherapy Design Targeting Endogenous Retrovirus (ERV)

MUNICH & COPENHAGEN, February 4, 2020— SIRION Biotech GmbH (“SIRION”), a world leader in viral vector-based gene delivery technologies for gene and cell therapy, and InProTher Aps (“InProTher”), a Danish start up supported by Novo Nordisk Foundation’s BioInnovation Institute (BII), today announced a broad licensing…

Steven Glazer joins Inprother as Medical Advisor

Steven Glazer has many years of international experience in healthcare and biotechnology. He has held a number of senior positions within pharmaceutical and bioengineering companies in Europe and the US, including Novo Nordisk, Zealand Pharma, BioInvent International and  Hansa Medical, and has gained deep knowledge…

Mathias Kroll joins InProTher as the new CEO

InProTher is very proud to annnounce that we have hired Mathias Kroll as the company’s new CEO. Mathias Kroll has got twelve years of research experience, split between the academic and biopharmaceutical sectors, and fourteen years of commercial experience mostly from business development but also…

WordPress Theme built by Shufflehound.